Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Campolina, Alessandro Gonçalves; Ty, Yuba; Tc, Decimoni; Leandro, Roseli Aparecida; Diz, MDPE; Hmd, Novaes; Pc, de Soárez

doi:10.3389/fpubh.2018.00205

Cited by 8 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differences in the costing method and in the organisation of health systems are two of the main reasons that makes economic evaluation results comparisons a challenge. Evidence has shown an increase in the number of health economic evaluations (HEEs) of cancer in Brazil [ 4 ]. However, although oral cancer is one of the five most common neoplasms among males, only 1.8% of the HEEs found were related to the oral cavity or pharyngeal cancer, from 1998 to 2013 [ 4 ] and none of them was a cost-of-illness study.…”

Section: Discussionmentioning

confidence: 99%

“…Evidence has shown an increase in the number of health economic evaluations (HEEs) of cancer in Brazil [ 4 ]. However, although oral cancer is one of the five most common neoplasms among males, only 1.8% of the HEEs found were related to the oral cavity or pharyngeal cancer, from 1998 to 2013 [ 4 ] and none of them was a cost-of-illness study. We did not find any specific study on the cost of oral cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Direct healthcare costs of lip, oral cavity and oropharyngeal cancer in Brazil

et al. 2021

View full text Add to dashboard Cite

The efficiency of public policies includes the measurement of the health resources used and their associated costs. There is a lack of studies evaluating the economic impact of oral cancer (OC). This study aims to estimate the healthcare costs of OC in Brazil from 2008 to 2016. This is a partial economic evaluation using the gross costing top-down method, considering the direct healthcare costs related to outpatients, inpatients, intensive care units, and the number of procedures, from the perspective of the public health sector. The data were extracted from the Outpatient and Inpatient Information System of the National Health System, by diagnosis according to the 10th Revision of the International Classification of Diseases, according to sites of interest: C00 to C06, C09 and C10. The values were adjusted for annual accumulated inflation and expressed in 2018 I$ (1 I$ = R$2,044). Expenditure on OC healthcare in Brazil was I$495.6 million, which was composed of 50.8% (I$251.6 million) outpatient and 49.2% (I$244.0 million) inpatient healthcare. About 177,317 admissions and 6,224,236 outpatient procedures were registered. Chemotherapy and radiotherapy comprised the largest number of procedures (88.8%) and costs (94.9%). Most of the costs were spent on people over 50 years old (72.9%) and on males (75.6%). Direct healthcare costs in Brazil for OC are substantial. Outpatient procedures were responsible for the highest total cost; however, inpatient procedures had a higher cost per procedure. Men over 50 years old consumed most of the cost and procedures for OC. The oropharynx and tongue were the sites with the highest expenditure. Further studies are needed to investigate the cost per individual, as well as direct non-medical and indirect costs of OC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Direct healthcare costs of lip, oral cavity and oropharyngeal cancer in Brazil

et al. 2021

View full text Add to dashboard Cite

show abstract

“…There are a few economic studies of prostate cancer in Brazil (23); however, none of them is on the economic burden of metastatic PC in the Brazilian PHS (SUS). Asano et al (24) carried out a study on the economic burden of PC with bone metastases between 2010 and 2015, but the study was conducted in the supplementary health scenario.…”

Section: Discussionmentioning

confidence: 99%

The cost of metastatic prostate cancer using time-driven activity-based costing

Alves

Etges

Tiscoski

et al. 2021

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Objective To estimate the cost of metastatic prostate cancer (mPC) treatment using the time-driven activity-based costing (TDABC) method from the perspective of a philanthropic hospital in the Brazilian public health system (PHS) and to identify determinants of costs. Methods We used data from patients who received docetaxel chemotherapy in the Brazilian PHS from September 2012 to May 2017. Direct medical costs were estimated with the TDABC microcosting method, taking into account the multiple departments and services the patients interacted with during their oncological treatment. Results The median overall survival of the forty-three patient sample was 1.8 years (95% CI 1.45–2.30), and the total cost of the sample was BRL 917.005 (USD 250,878). The median monthly cost per patient was BRL 20.201 (USD 5,526). The end-of-life cost per patient using the TDABC method was BRL 5.151 (USD 1,409). Patients who had received previous treatment at the center registered the lowest cost for hospitalizations and exams, suggesting an opportunity to better manage healthcare resources. Conclusions This is the first study on the economic burden of mPC in the Brazilian PHS using the TDABC costing evaluation method. Accurate cost information obtained with the TDABC can be helpful in guiding disease management to guarantee better use of ever-scarcer resources.

show abstract

“…O câncer de mama foi o mais estudado e a maioria dos estudos econômicos completos era de análise de custo-efetividade. Nesse estudo de Campolina et al, a RCEI por QALY ganho estava entre USD 466.45 e USD 374,630.96, o que corresponderia a aproximadamente R$ 2.100,00 a R$ 1,7 milhão de reais (usando a taxa de câmbio de 1 USD = R$ 4,50, de 04/03/2020) (Campolina et al, 2018). No nosso estudo, somente dois estudos utilizaram o QALY; a maioria utilizou o valor de anos de vida ganho, sem ajuste para a qualidade de vida.…”

Section: Métodosunclassified